Pair Name	Mitocurcumin, Cytarabine
Partner Name	Cytarabine
Disease Info	[ICD-11: 2B33.4]	Leukemia		Investigative
Biological Phenomena	Induction-->Apoptosis and DNA damage
Gene Regulation	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	BCL-xL	hsa598
	Up-regulation	Cleavage	CASP3	hsa836
	Down-regulation	Expression	CCND1	hsa595
	Down-regulation	Expression	CHEK1	hsa1111
	Up-regulation	Phosphorylation	H2AX	hsa3014
	Up-regulation	Cleavage	JUN	hsa3725
	Up-regulation	Activity	MAPK14	hsa1432
	Up-regulation	Phosphorylation	MAPK8	hsa5599
	Down-regulation	Expression	MCL1	hsa4170
	Down-regulation	Expression	MYC	hsa4609
	Up-regulation	Cleavage	PARP1	hsa142
	Down-regulation	Expression	RAD51	hsa5888
	Down-regulation	Expression	XIAP	hsa331
In Vitro Model	MOLM-13	Adult acute myeloid leukemia	Homo sapiens (Human)	CVCL_2119
	HL-60	Adult acute myeloid leukemia	Homo sapiens (Human)	CVCL_0002
In Vivo Model	A total of 1.5 × 106 MOLM13 cells were injected subcutaneously into the flank region of 6–8 weeks-old NOD/SCID mice. When tumors grew to 150–200 mm3, the mice were randomized into three groups (n = 9/group) followed by intraperitoneal administration of 0.1% DMSO daily, MitoC (2 mg/kg) on alternate days, or cytarabine (20 mg/kg) daily for 12 days.
Result	The data suggest that MitoC exploits stress-induced leukemic oxidative environment to up-regulate JNK/p38 signaling to lead to apoptosis and can potentially overcome Cytarabine resistance via ROS/p21/CHK1 axis.